-
21.发明公开
公开(公告)号：KR1020170065014A
公开(公告)日：2017-06-12
申请号：KR1020160163634
申请日：2016-12-02
Applicant: 서울대학교산학협력단
IPC: A61K31/575 , A61K31/704 , A61K31/56
CPC classification number: A61K31/575 , A61K31/56 , A61K31/704
Abstract: 본발명은갈락토실화된폴리에틸렌글리콜-리토콜린산을유효성분으로함유하는암의예방또는치료용조성물에관한것으로, 본발명에따른갈락토실화된폴리에틸렌글리콜-리토콜린산나노입자는아폽토시스를통한세포사멸을유의적으로유발시킴으로써, 암세포의증식및 전이를억제하는효과가우수하므로, 암의예방, 개선또는치료에유용하게사용될수 있다.
Abstract translation: 本发明是一种半乳糖失火聚乙二醇 - 对，乳杆菌属失火聚乙二醇在根据本发明去涉及胆碱酸利托那韦的用于预防或含有如通过细胞凋亡活性成分-利托胆碱酸纳米颗粒治疗癌症的组合物 通过有效诱导细胞凋亡，其具有抑制癌细胞增殖和转移的优异效果，因此可用于预防，改善或治疗癌症。
-
22.发明公开
公开(公告)号：KR1020170057857A
公开(公告)日：2017-05-25
申请号：KR1020160153654
申请日：2016-11-17
Applicant: 서울대학교산학협력단
IPC: A61K48/00 , A61K39/395 , A61K31/713 , G01N33/53 , A61K39/00
Abstract: 본발명은 FCHo1의활성을촉진또는억제하여세포분열을조절하기위한조성물및 이를이용한방법에관한것이다. 본발명의 FCHo1 활성조절제는세포분열에서중요한인자로기능하는 FCHo1을타깃으로하여이의활성을촉진또는억제시킴으로써, 세포분열을촉진하거나세포분열을억제할수 있으므로세포분열과관련된질병의치료에효과적으로활용될수 있다.
Abstract translation: 本发明涉及通过促进或抑制FCHO1的活性来调节细胞分裂的组合物及使用该组合物的方法。 FCHO1本发明的活性调节剂，通过使用作为目标的FCHO1这在细胞分裂作为一个重要的因素，以促进或抑制其活性，因为它能够促进细胞分裂或抑制细胞分裂的疾病与细胞分裂相关的处理能够有效地利用 有。
-
公开(公告)号：KR101703807B1
公开(公告)日：2017-02-09
申请号：KR1020140087284
申请日：2014-07-11
Applicant: 서울대학교산학협력단
Abstract: 본발명은미토콘드리아유래활성산소발현량측정용신규한세포주, 이를포함하는조성물및 이의용도에관한것이다. 보다상세하게는, 하기의제1 재조합바이러스벡터및 제 2 재조합바이러스벡터로형질전환된세포주를제공한다: 상기제1 재조합벡터는, ROMO1(Reactive oxygen species modulator 1) 프로모터; 및상기서열에작동적으로연결된(operatively linked) 리포터유전자-코딩뉴클레오타이드서열을포함하고; 상기제2 재조합벡터는 CMV(Cytomegalovirus) 프로모터; 및상기서열에작동적으로연결된(operatively linked) 리포터유전자-코딩뉴클레오타이드서열을포함한다. 또한, 상기세포주를포함하는활성산소발현량측정용조성물, 독성물질스크리닝용조성물, 상기세포주의제작방법및 간독성유발물질스크리닝방법을제공한다.
Abstract translation: 本发明涉及用于测量线粒体活性氧的表达水平的新型细胞系，含有它们的组合物及其用途。 更具体地，本发明提供用下列第一和第二重组病毒载体转化的细胞系。 第一重组载体包含：活性氧调节剂1（ROMO1）启动子; 和与该序列有效连接的报告基因编码核苷酸序列。 第二重组载体包含：巨细胞病毒（CMV）启动子; 和与该序列有效连接的报告基因编码核苷酸序列。 此外，提供了用于测量含有细胞系的线粒体活性氧的表达水平的组合物，用于筛选有毒物质的组合物，生产细胞系的方法以及用于筛选引起肝毒性的物质的方法。
-
公开(公告)号：KR1020140118458A
公开(公告)日：2014-10-08
申请号：KR1020130034414
申请日：2013-03-29
Applicant: (주)크로엔 , 서울대학교산학협력단
Abstract: The present invention relates to an SDA/PEI (PSMT) copolymer in which polyethyleneimine (PEI) and sorbitol diacrylate (SDA) are combined, a gene carrier in which gene is combined to the SDA/PEI (PSMT) copolymer and a pharmaceutical composition for the prevention or treatment of cancer including the gene carrier as an active ingredient. The SDA/PEI (PSMT) copolymer according to the present invention forms a PSMT/gene complex by exhibiting high bondability in genes (DNA, RNA and the like). The PSMT/gene complex is able to be brought into cells since the PSMT/gene complex has a small size of 200 nm or less, is nontoxic and is able to be usefully used in the prevention or treatment for cancer and a gene carrier by excellent cancer cell targetability.
Abstract translation: 本发明涉及其中组合聚乙烯亚胺（PEI）和山梨糖醇二丙烯酸酯（SDA）的SDA / PEI（PSMT）共聚物，其中基因与SDA / PEI（PSMT）共聚物组合的基因载体和用于 预防或治疗包括基因载体作为活性成分的癌症。 根据本发明的SDA / PEI（PSMT）共聚物通过在基因（DNA，RNA等）中表现出高的结合性而形成PSMT /基因复合物。 由于PSMT /基因复合体具有200nm以下的小尺寸，所以能够将PSMT /基因复合体引入细胞中，是无毒的，并且能够有效地用于预防或治疗癌症和基因载体 癌细胞靶向性。
-
公开(公告)号：KR1020120111719A
公开(公告)日：2012-10-10
申请号：KR1020120030815
申请日：2012-03-26
Applicant: 서울대학교산학협력단
CPC classification number: A61K31/13 , C08F222/1006 , C12N15/87
Abstract: PURPOSE: A spermine copolymer is provided to remarkably improve transduction effectiveness without cytotoxicity as a hexane-carrier, thereby capable of being used as a hexane-carrier for gene-therapy. CONSTITUTION: A spermine copolymer of which primary amine or secondary amine is combined with at least one acrylate terminal of a linker through an addition reaction is represented by chemical formula 1. A molecular weight of the copolymer is 3-15 kDa. Polyethyleneglycol, galactosylated polyethyleneglycol, folate, mannose, or a combination thereof is additionally combined to the spermine copolymer. A hexane-transfer composite is that a therapy hexane is combined with the spermine copolymer. The combination ratio of the therapy hexane and the spermine copolymer is 1:5 - 1:50. [Reference numerals] (AA) Each of R1 and R3 is independently H or CH3; (BB) R2 is independently H or; (CC) R4 is independently H or CH3, n, k, j is independetly 1, 2 or 3, and m, l, i is independently 0, 1 or 2
Abstract translation: 目的：提供精胺共聚物以显着提高转染效率，而不会作为己烷 - 载体的细胞毒作用，从而能够用作基因治疗的己烷载体。 构成：其中伯胺或仲胺通过加成反应与连接体的至少一个丙烯酸酯末端结合的精胺共聚物由化学式1表示。共聚物的分子量为3-15kDa。 聚乙二醇，半乳糖基化聚乙二醇，叶酸，甘露糖或其组合另外与精胺共聚物组合。 己烷转移复合物是将处理己烷与精胺共聚物结合。 治疗己烷和精胺共聚物的组合比为1:5〜1:50。 （标号）（AA）R 1和R 3各自独立地为H或CH 3; （BB）R2独立地为H或; （CC）R4独立地为H或CH 3，n，k，j独立地为1,2或3，m，l，i独立地为0,1或2
-
Patent Agency Ranking26.发明公开신장세포특이적인 펩타이드 및 폴리에스테르아민 중합체를 포함하는 유전자 전달체 및 이를 포함한 신장 섬유증 예방 또는 치료용 조성물. 有权包含肾细胞特异性肽和聚氨酯的基因递送复合物及其组合物，用于预防或治疗肾脏纤维变性
公开(公告)号：KR1020120098022A
公开(公告)日：2012-09-05
申请号：KR1020110017687
申请日：2011-02-28
Applicant: 서울대학교산학협력단 , 이연제약주식회사
Abstract: PURPOSE: A gene delivery system containing renal cell-specific peptides and polyester amine polymers is provided to effectively deliver HGF gene to a target site and to suppress fibrosis. CONSTITUTION: A gene delivery system contains renal cell-specific peptides and polyester amine polymers. The renal cell-specific peptide is HOOC-ELRGDRAHW-NH_2. The polyester amine polymer is a copolymer of polyethylenimine and glycerol dimethacrylate. The delivery system is prepared by amide bond of a carboxyl group of rental cell-specific peptides and an amine group of polyester amine polymers. A HGF gene contains a base of sequence number 1. A composition for preventing or treating rental fibrosis contains a gene delivery complex.
Abstract translation: 目的：提供含有肾细胞特异性肽和聚酯胺聚合物的基因递送系统，以有效地将HGF基因递送至靶位点并抑制纤维化。 构成：基因递送系统含有肾细胞特异性肽和聚酯胺聚合物。 肾细胞特异性肽是HOOC-ELRGDRAHW-NH_2。 聚酯胺聚合物是聚乙烯亚胺和二甲基丙烯酸甘油酯的共聚物。 递送系统由出租细胞特异性肽的羧基的酰胺键和聚酯胺聚合物的胺基组成。 HGF基因含有序列号1的碱基。用于预防或治疗纤维化出血的组合物含有基因递送复合物。
-
27.发明公开폐암 화상진단을 위한 Ｃｙ5.5로 표지된 폴레이트-ＰＥＧ-초상자성 산화철 나노입자 및 이를 이용한 폐암 화상진단용 조영제 无效标记为CY5.5的肺结核-PEG-超级氧化铁氧化物纳米颗粒用于肺癌成像和对照用于包含其的肺癌成像
公开(公告)号：KR1020110111779A
公开(公告)日：2011-10-12
申请号：KR1020100031028
申请日：2010-04-05
Applicant: 서울대학교산학협력단
CPC classification number: A61K49/0423 , A61K33/08 , G01N2800/7028
Abstract: 본 발명은 폴레이트-PEG를 제조하고, 이를 이용하여 초상자성 산화철 나노입자를 코팅한 후, 표면에 광학 화상진단을 위한 근적외선형광 염료를 표지시킨 Fol-PEG-SPIONs-Cy5.5 및 이를 이용한 폐암 화상진단용 조영제에 관한 것으로, 본 발명에 따른 Fol-PEG-SPIONs-Cy5.5는 낮은 세포독성을 나타내고, in vitro 및 in vivo 모두에서 암세포에 대한 표적화 운반 효율을 증진시키며, 종양 위치를 보다 명료하게 확인할 수 있는 효과가 있다.
-
公开(公告)号：KR1020100111878A
公开(公告)日：2010-10-18
申请号：KR1020090030324
申请日：2009-04-08
Applicant: 서울대학교산학협력단
CPC classification number: A61K48/00 , A61K31/7105 , A61K31/711 , C12Q2525/207
Abstract: PURPOSE: An inhibitor of sodium-dependent inorganic phosphate transporter-2b gene or protein expressed from the gene and a composition for treating cancer containing the same are provided to suppress generation and growth of cancer. CONSTITUTION: An inhibitor of sodium-dependent inorganic phosphate transporter-2b gene is siRNA(small interfering RNA) or shRNA(small hairpin RNA) of sodium-dependent inorganic phosphate transporter-2b gene. A composition for treating cancer contains the inhibitor of sodium-dependent inorganic phosphate transporter-2b gene. The inhibitor suppresses AKT activation. A composition for screening anticancer drug contains the sodium-dependent inorganic phosphate transporter-2b gene or protein expressed from the gene.
Abstract translation: 目的：提供从该基因表达的钠依赖型无机磷酸盐转运蛋白-2b基因或蛋白质的抑制剂和用于治疗含有该组合物的癌症的组合物，以抑制癌症的产生和生长。 构成：钠依赖型无机磷酸盐转运蛋白-2b基因的抑制剂是钠依赖型无机磷酸盐转运蛋白-2b基因的siRNA（小干扰RNA）或shRNA（小发夹RNA）。 用于治疗癌症的组合物含有依赖于钠的无机磷酸盐转运蛋白-2b基因的抑制剂。 抑制剂抑制AKT活化。 用于筛选抗癌药物的组合物含有从该基因表达的钠依赖性无机磷酸转运蛋白-2b基因或蛋白质。
-
公开(公告)号：KR1020100102273A
公开(公告)日：2010-09-24
申请号：KR1020090020563
申请日：2009-03-11
Applicant: 서울대학교산학협력단
IPC: G01N33/52 , G01N33/533
Abstract: PURPOSE: A qualitative method of a multiple marker is provided to performing qualitation of high sensitivity and selectivity using F-SERS dots. CONSTITUTION: A qualitative method for a multiple marker comprises: a step of treating multiple marker-specific fluorescence-surface enhanced raman scattering(SERS) dot mixture to a sample; and a step of measuring raman signal corresponding to the multiple marker to calculate relative amount of the multiple marker. The SERS dot comprises: a metal nanoparticle layer containing a metal on the surface of silica nanoparticle; a raman probe and fluorescence probe layer formed at the metal nanoparticle layer; a functional layer; and a reaction molecule attached on the functional layer. The diameter of the silica nanoparticle is 50-300nm. The metal is gold, silver, palladium, platinum, aluminum, iridium, osmium, rhodium or ruthenium. The functional group is thiol group(-SH), amine group(-NH_2) or carboxyl group(-COOH).
Abstract translation: 目的：提供多重标记的定性方法，以使用F-SERS点进行高灵敏度和选择性的定性。 构成：多重标记的定性方法包括：将多个标记特异性荧光表面增强拉曼散射（SERS）点混合物处理到样品的步骤; 以及测量与所述多个标记相对应的拉曼信号以计算所述多个标记的相对量的步骤。 SERS点包括：在二氧化硅纳米颗粒的表面上含有金属的金属纳米颗粒层; 在金属纳米颗粒层形成的拉曼探针和荧光探针层; 功能层; 和附着在功能层上的反应分子。 二氧化硅纳米颗粒的直径为50-300nm。 金属是金，银，钯，铂，铝，铱，锇，铑或钌。 官能团是硫醇基（-SH），胺基（-NH2）或羧基（-COOH）。
-
公开(公告)号：KR1020100095940A
公开(公告)日：2010-09-01
申请号：KR1020090014996
申请日：2009-02-23
Applicant: 서울대학교산학협력단
IPC: A61K47/48 , A61P35/00 , A61K31/337 , A61K31/202
CPC classification number: A61K47/12 , A61K9/06 , A61K31/337 , A61K47/30
Abstract: PURPOSE: A novel anti-tumor acid topical drug delivery system is provided to enhance in vitro PTX cytotoxicity and to significantly reduce tumor volume in vivo. CONSTITUTION: A drug delivery system is formed by loading paclitaxel(PTX) to conjugated linoleic acid(CLA)-binding poloxamer hydrogel. An anti-tumor active pharmaceutical composition contains PTX loading CLA-binding poloxamer hydrogel drug delivery system as an active ingredient.
Abstract translation: 目的：提供一种新的抗肿瘤酸局部药物递送系统，以增强体外PTX细胞毒性并显着降低体内肿瘤体积。 构成：通过将紫杉醇（PTX）加载到共轭亚油酸（CLA）结合的泊洛沙姆水凝胶中形成药物递送系统。 抗肿瘤活性药物组合物含有PTX负载CLA结合泊洛沙姆水凝胶药物递送系统作为活性成分。
-
-
-
-
-
-
-
-
-
Search Results
56
records
(took 0.084 seconds)
